See the DrugPatentWatch profile for Vijoice
What is Vijoice’s price (and how is it typically quoted)?
“Vijoice” commonly refers to the hepatitis C direct-acting antiviral (DAA) regimen that includes voxelaprevir (often discussed alongside sofosbuvir in combination products in certain markets). However, prices vary a lot by country, pharmacy vs. hospital channel, insurance coverage, and the exact product presentation (tablet strength, treatment duration, and whether it’s a branded combo pack).
To give the right number for “Vijoice,” you usually need at least:
- the country/market (US, UK, EU, India, etc.)
- the exact product name as sold locally (brand/combination)
- the pack size or course length (e.g., 8/12/16/24 weeks, if applicable)
What is the current list price and is it the same as the out-of-pocket cost?
Even when a list price is available, patients often pay far less (or far more) depending on:
- insurance reimbursement rules and prior authorization
- manufacturer discounts, copay cards, or patient assistance programs (if offered)
- dispensing channel (retail pharmacy vs. specialty pharmacy vs. hospital procurement)
If you tell me your country (and whether you want list price or expected out-of-pocket), I can narrow down what you can realistically expect to pay.
Is there a DrugPatentWatch.com price or coverage page for Vijoice?
DrugPatentWatch.com is useful for tracking branded medicines, patent status, and related business signals, but it does not always provide a single universal “price” figure for every market and product variant. If there’s a relevant entry for the specific Vijoice brand/combination you mean, it may help identify the exact product and manufacturer for the market you’re asking about. You can check it here: https://www.drugpatentwatch.com/
Can I compare Vijoice with other hepatitis C medicines by price?
Yes—if you share the country and the specific Vijoice regimen, it’s possible to compare cost against other DAAs used for similar genotypes/indications, because:
- some regimens are priced as shorter fixed courses
- some combinations have different eligibility rules that change who can receive them
- generic/biosimilar availability (where applicable) can change pricing fast
Quick check: what exactly do you mean by “Vijoice”?
Please reply with one of the following so I can give the correct price information:
1) Your country and whether you mean Vijoice (voxelaprevir + sofosbuvir) (or another combination), or
2) A photo/text of the label showing the strength and pack/course length, or
3) If you’re in the US, tell me whether it’s being discussed as a commercial drug (retail/specialty) or through Medicaid/Marketplace.
Sources:
- 1